Administration, Intravesical
"Administration, Intravesical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
| Descriptor ID |
D000283
|
| MeSH Number(s) |
E02.319.267.120.505
|
| Concept/Terms |
Administration, Intravesical- Administration, Intravesical
- Intravesical Drug Administration
- Drug Administration, Bladder
- Administration, Intravesical Drug
- Administrations, Intravesical Drug
- Drug Administration, Intravesical
- Drug Administrations, Intravesical
- Intravesical Drug Administrations
- Intravesical Administration
- Administrations, Intravesical
- Intravesical Administrations
- Bladder Drug Administration
- Administration, Bladder Drug
- Administrations, Bladder Drug
- Bladder Drug Administrations
- Drug Administrations, Bladder
Instillation, Bladder- Instillation, Bladder
- Bladder Instillation
- Bladder Instillations
- Instillations, Bladder
- Intravesical Instillation
- Instillation, Intravesical
- Instillations, Intravesical
- Intravesical Instillations
Intravesical Injection- Intravesical Injection
- Injections, Intravesical
- Injection, Intravesical
- Intravesical Injections
|
Below are MeSH descriptors whose meaning is more general than "Administration, Intravesical".
Below are MeSH descriptors whose meaning is more specific than "Administration, Intravesical".
This graph shows the total number of publications written about "Administration, Intravesical" by people in this website by year, and whether "Administration, Intravesical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Administration, Intravesical" by people in Profiles.
-
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series. Urol Oncol. 2026 Mar; 44(3):110984.
-
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu?rin in Patients with Bacillus Calmette-Gu?rin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2025 Apr; 8(2):469-476.
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 07; 212(1):74-86.
-
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Gu?rin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Gu?rin Treatment. Clin Genitourin Cancer. 2024 Jun; 22(3):102059.
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
-
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
-
The Who, What, When, Where, and Why of Bacillus Calmette-Gu?rin-unresponsive Bladder Cancer. Eur Urol. 2021 04; 79(4):437-439.
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
-
Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. Anticancer Res. 2020 Sep; 40(9):5295-5299.